Clinical Trial Update: Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity [Phase 3]

View source ↗

Summary

Phase 3 trial assessing methylphenidate late formula to reduce cannabis use in young patients with cannabis-related issues and ADHD; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate Late Formula (methylphenidate)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: TERMINATED